Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Decreases By 39.8%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 6,500 shares, a decline of 39.8% from the October 31st total of 10,800 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 8,900 shares, the short-interest ratio is presently 0.7 days.

Anebulo Pharmaceuticals Price Performance

Shares of Anebulo Pharmaceuticals stock opened at $1.43 on Thursday. The company’s fifty day moving average price is $1.83 and its two-hundred day moving average price is $2.05. The firm has a market capitalization of $37.08 million, a PE ratio of -4.77 and a beta of -1.00. Anebulo Pharmaceuticals has a 52-week low of $1.25 and a 52-week high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.08. Analysts predict that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Benchmark reissued a “speculative buy” rating and set a $8.00 price objective on shares of Anebulo Pharmaceuticals in a report on Tuesday, November 19th.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.